article thumbnail

Global comparator data signal “alarm bells” for UK Government, says APBI

pharmaphorum

The paper, by a team from Imperial College London, concluded that the FDA gave the go ahead to 95% of the 89 products approved between 2010 and 2019 before EMA, with the Europeans trailing the Americans by a median of 241 days. Between 2012 and 2020, it averaged 3% each year, whereas Spain’s share, for example, had increased from 2.6%

article thumbnail

Sales Force Outsourcing – MaBiCo

MaBiCo

There are several reasons why pharmaceutical companies outsource their sales force to a CSO. However the most important of all is experience in the pharma industry. Many CSOs are considered to have the necessary expertise in the pharmaceutical sector. However there are some major differences among them.

Sales 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics

European Pharmaceutical Review

Dr Michael Davidson is CEO of biotech company NewAmsterdam Pharma. We are hopeful that NewAmsterdam Pharma is part of that solution with obicetrapib.” NewAmsterdam Pharma is moving forward into our Phase III trials in the high LDL populations and ultimately, we want to show the benefit of obicetrapib on reducing cardiovascular events.

Pharma 76
article thumbnail

Leading innovators in ssRNA virus peptides for the pharmaceutical industry

Pharmaceutical Technology

Patent volumes related to ssRNA virus peptides Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies Johnson & Johnson 419 Unlock company profile GSK 419 Unlock company profile C. J&J develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products.

article thumbnail

The rise and rise of ESG in the pharmaceutical sector – is a zero-waste supply?chain possible?? 

Pharmaceutical Technology

Of the world’s 20 largest pharmaceutical companies, 17 have launched programmes tailored towards increasing medication access in low- and middle-income countries – up from just eight in 2010. Figure 1: Social media posts from pharmaceutical firms mentioning “environment”. Source: GlobalData.